| Total cases; n  =  1457 | TyG index  <  8.55; n  =  728 | TyG index ≥ 8.55; n  =  729 | p value |
---|---|---|---|---|
Age (years) | 62.34  ±  8.00 | 62.31  ±  8.06 | 62.37  ±  7.95 | 0.894 |
Female/male (%) | 767/690 (52.6/47.4) | 408/320 (56.0/44.0) | 359/370 (49.2/50.8) | 0.010 |
BMI | 24.81  ±  3.55 | 23.55 (21.66–25.79) | 25.35 (23.42–27.65) | < 0.001 |
Waist circumference | 84.28  ±  9.75 | 81.5 (75.0–88.0) | 86.5 (80.0–93.0) | < 0.001 |
Smoking (%) | 260 (17.8) | 117 (16.1) | 143 (19.6) | 0.087 |
Underlying disease | ||||
 Hypertension (%) | 520 (35.7) | 212 (29.1) | 308 (42.2) | < 0.001 |
 Anti-hypertensive agents (%) | 239 (16.4) | 93 (12.8) | 146 (20.0) | < 0.001 |
 DM (%) | 202 (13.9) | 57 (7.8) | 145 (19.9) | < 0.001 |
 CKD (%) | 282 (19.4) | 129 (17.8) | 153 (21.0) | 0.127 |
 Metabolic syndrome (%) | 453 (31.1) | 90 (12.4) | 363 (49.8) | < 0.001 |
 Overweight (%) | 633 (43.4) | 239 (32.8) | 394 (54.0) | < 0.001 |
 LDL  ≥  130 mg/dL (%) | 554 (38.0) | 239 (32.8) | 315 (43.2) | < 0.001 |
Laboratory data | ||||
 Total cholesterol (mg/dl) | 197.66  ±  35.30 | 193 (168–215) | 202 (177–223) | < 0.001 |
 HDL (mg/dl) | 55.16  ±  14.11 | 58 (50–69) | 49 (42–56) | < 0.001 |
 LDL (mg/dl) | 120.87  ±  32.57 | 116 (96–137) | 124 (102–144) | < 0.001 |
 Fasting glucose (mg/dl) | 101.49  ±  28.16 | 92 (87–98) | 100 (92–111) | < 0.001 |
 HbA1c (%) | 6.01  ±  0.98 | 5.7 (5.5–6.0) | 5.9 (5.6–6.4) | < 0.001 |
 Uric acid | 5.84  ±  1.50 | 5.4 (4.6–6.3) | 6.1 (5.1–7.1) | < 0.001 |
 hs-CRP | 0.22  ±  0.38 | 0.069 (0.033–0.190) | 0.102 (0.041–0.245) | 0.975 |
 Triglyceride (mg/dl) | 121.85  ±  78.47 | 77 (60–90) | 143 (123–186) | < 0.001 |
 eGFR (ml/min/1.73 m2) | 83.33  ±  28.30 | 82.62  ±  27.24 | 84.03  ±  29.32 | 0.341 |
 Triglyceride glucose index | 8.57  ±  0.58 | 8.18 (7.95–8.36) | 8.88 (8.70–9.21) | < 0.001 |
 Mean cIMT (mm) | 0.68  ±  0.13 | 0.65 (0.60–0.75) | 0.70 (0.60–0.75) | 0.003 |
 cIMT  ≥  0.75 mm (%) | 417 (28.6) | 189 (26.0) | 228 (31.3) | 0.028 |